AMYOTROPHIC LATERAL SCLEROSIS (ALS)
Clinical trials for AMYOTROPHIC LATERAL SCLEROSIS (ALS) explained in plain language.
Never miss a new study
Get alerted when new AMYOTROPHIC LATERAL SCLEROSIS (ALS) trials appear
Sign up with your email to follow new studies for AMYOTROPHIC LATERAL SCLEROSIS (ALS), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New spinal injection tested for ALS patients
Disease control OngoingThis early-stage study is testing the safety of a single spinal injection called RJK002 in people with ALS. The trial involves 9 participants who were diagnosed within the last 2 years and still have good breathing and movement function. Researchers will monitor for side effects …
Matched conditions: AMYOTROPHIC LATERAL SCLEROSIS (ALS)
Phase: PHASE1 • Sponsor: RJK Biopharma Ltd • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC
-
New hope for ALS patients: experimental drug trial seeks to slow deadly disease
Disease control ENROLLING_BY_INVITATIONThis clinical trial is testing whether an experimental drug called NUZ-001 can slow down ALS progression and help patients maintain physical function longer. The study will involve 160 people with ALS who will receive either the active drug or a placebo. Researchers will measure …
Matched conditions: AMYOTROPHIC LATERAL SCLEROSIS (ALS)
Phase: PHASE2, PHASE3 • Sponsor: Merit E. Cudkowicz, MD • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC
-
New hope for ALS patients: experimental drug aims to slow deadly disease
Disease control OngoingThis study is testing whether a new oral drug called Usnoflast can slow the progression of ALS (Lou Gehrig's disease). It involves 240 adults with early-stage ALS who will take either the drug or a placebo for 36 weeks, followed by an optional 16-week period where everyone gets t…
Matched conditions: AMYOTROPHIC LATERAL SCLEROSIS (ALS)
Phase: PHASE2 • Sponsor: Zydus Therapeutics Inc. • Aim: Disease control
Last updated Mar 25, 2026 14:08 UTC
-
Race against time: new drug aims to slow devastating ALS
Disease control OngoingThis study is testing whether an experimental drug called VHB937 can slow the progression of early-stage ALS (Lou Gehrig's disease). It will involve 251 adults who have had ALS symptoms for less than two years. Participants will receive either the drug or a placebo for 40 weeks, …
Matched conditions: AMYOTROPHIC LATERAL SCLEROSIS (ALS)
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Mar 05, 2026 13:59 UTC
-
Robotic glove trial aims to give ALS patients a helping hand
Symptom relief ENROLLING_BY_INVITATIONThis small pilot study is testing whether using a special robotic glove can help people with ALS maintain hand strength and dexterity, and improve their quality of life. Five participants will use the glove daily for 8 weeks while researchers measure changes in their grip, fine m…
Matched conditions: AMYOTROPHIC LATERAL SCLEROSIS (ALS)
Phase: NA • Sponsor: Nova Southeastern University • Aim: Symptom relief
Last updated Mar 23, 2026 15:17 UTC